PHGE - BiomX Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.3100 |
| Open | 0.3100 |
| Bid | 0.3046 x 1300 |
| Ask | 0.3143 x 900 |
| Day's Range | 0.2973 - 0.3223 |
| 52 Week Range | 0.1320 - 1.1700 |
| Volume | |
| Avg. Volume | 262,691 |
| Market Cap | 13.799M |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7500 |
| Earnings Date | Jul 06, 2023 - Jul 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
GlobeNewswireBiomX Reports First Quarter 2023 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part 2 Expected in Third Quarter of 2023 Second and Final Closing of PIPE Investment Completed, Raising Total Gross Proceeds of $7.5 million; Cash Runway into the Third Quarter of 2024 Jason M. Marks and Michael E. Dambach Appointed to Board of Directors Company Will Host a Conference Call and Webcast Today at 8:00 am ET CAMBRIDGE, Mass. and NESS Z
- GlobeNewswire
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors. “We are pleased to welcome Jason and Michael to our Board of Directors,” said Jonathan Solomon, Chief Executive Officer of BiomX Inc. “Each of
- GlobeNewswire
BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m. ET, to report first quarter 2023 financial results and provide business updates. To participate in the conference cal
- GlobeNewswire
BiomX Announces Second Closing of $7.5 Million Private Placement
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its recently announced $7.5 million private placement (“PIPE”) investment. On February 22, 2023, the Company announced that it entered into a securities purchase agreement (“SPA”) with a selected group of
- GlobeNewswire
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”) Patient Enrollment Continues in Part 2 of Phase 1b/2a Trial with Results Expected in Third Quarter of 2023 Cash Runway Through at Least Mid-2024 Company Will Host a Conference Call and Webcast Today at 8:00 am ET CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-sta
- GlobeNewswire
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 29th, 2023, at 8:00 a.m. ET, to report fourth quarter and full year 2022 financial results and provide business updates. To participate
- GlobeNewswire
BiomX Announces $7.5 Million Private Placement
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement (“SPA”) with a select group of institutional and individual investors (the “Investors”), including existing investors OrbiMed and the Cystic Fibrosis Foundation, to issu
- GlobeNewswire
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BX004 therapy safe and well-tolerated across all patients and dose levels Preliminary signals of efficacy also observed, with notable reductions in bacterial burden Dosing in patients in Part 2 initiated, results expected in Q3 23 Company to host webcast/cc to discuss Part 1 data today at 9:00 am ET CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered
- GlobeNewswire
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022. H.C Wainwright 1st Annual Investor Conference on Bacteriophage Date & Tim
- GlobeNewswire
BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023 Announced Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease Cash Runway Through at Least Mid-2024 Company Will Host a Conference Call and Webcast Today at 8:00 am ET NESS ZIONA, Israel, Nov. 09, 2022 (GLOBE NEW
- GlobeNewswire
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates. To participate in the conference call, p
Business WireBiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
NESS ZIONA, Israel, September 11, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.
Business WireBiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
BRANFORD, Conn. & NESS ZIONA, Israel, August 10, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022.
Business WireBiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
BRANFORD, Conn. & NESS ZIONA, Israel, August 07, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call,
Business WireBiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
BRANFORD, Conn. & NESS ZIONA, Israel, August 04, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled "Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation" in the journal, Cell. The research was conducted across several organizati
Business WireBiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
BRANFORD, Conn. & NESS ZIONA, Israel, July 06, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange (the "TASE").
Business WireBoehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
BRANFORD, Conn. & NESS ZIONA, Israel, June 28, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or "Company") announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease ("IBD"). BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.
Business WireBiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
BRANFORD, Conn. and NESS ZIONA, Israel, June 27, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the dosing of the first two patients in the Company’s Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with cystic fibrosis ("CF").